Alignment Healthcare (ALHC) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.25
- Estimate
- $0.20
- Surprise
- +24.4%
- Revenue (period 2026-06-30)
- $1.34B
- Score today
- 5.9/10
Revenue source: xbrl.
How the report landed
Alignment Healthcare (ALHC) beat the $0.20 estimate with diluted EPS of $0.25 — a large 24.4% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ALHC Sell at 5.9/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +24.4% surprise compares with a +310.6% four-quarter average. Next scheduled report: 2026-10-29.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- Concentration risk — Customer: CMS contracts
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5)
- Leverage penalty (D/E 1.2): -0.5
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $13.54
- Price target
- $20.95
- Stop
- $12.60
- Upside to target
- +54.7%
- Reward-to-risk
- 6.7:1
The stock trades at 71.5× trailing but 18.1× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
ALHC at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Healthcare Plans
- Market cap
- $2.82B
- P/E (fwd)
- 18.1
- P/E (ttm)
- 71.5
- 52-week range
- $12.70–$25.12
- Off 52-week high
- 46.1%
- RSI (14)
- 43
- Volume vs avg
- 0.97×
- Score today
- 5.9/10